IDEX Corporation (NYSE:IEX) entered into agreement to acquire Muon B.V. from Rivean Capital B.V. for €700 million on September 13, 2022. Deal is subject to customary post-closing adjustments. This acquisition is expected to be funded by IDEX using cash on hand and proceeds from its revolving credit facility. Transaction is expected to be funded with $350 million (€349.79 million) of cash on hand, $150 million (€149.91) from IDEX's revolving Facility and $200 million (€199.88 million) of proceeds from a new debt issuance. Muon Group will report into IDEX's Health & Science Technology (HST) segment. Muon reported an annual sales of approximately €140.0 million. The transaction is subject to regulatory approvals and consultation with the Dutch works council. Deal is expected to close in the fourth quarter. As of October 26, 2022, IDEX expects to close the transaction by the end of the fourth quarter of 2022. William Blair acted as exclusive financial advisor to the shareholders of Muon Group and Lennard Keijzer, Henk van Ravenhorst, Lennard Keijzer, Henk van Ravenhorst, Daniël van Gerven and Stephanie The of De Brauw Blackstone Westbroek N.V. acted as legal advisors to Rivean Capital B.V. in this transaction. Sidley Austin and Houthoff also advised on the transaction.

IDEX Corporation (NYSE:IEX) completed the acquisition of Muon B.V. from Rivean Capital B.V. for approximately $710 million (€670 million)on November 18, 2022. The cash purchase price was funded with $342.6 million (€322.1 million) of cash on hand, $170.4 million (€160.2 million) of proceeds from IDEX 's Revolving Facility and $200 million (€188 million) of proceeds from IDEX's Term Facility.